title: Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
abstract: Zileuton is a potent and specific inhibitor of 5-lipoxygenase, the first dedicated enzyme in the metabolism of arachidonic acid to the leukotrienes. The leukotrienes have been implicated in numerous pathological conditions. Zileuton was given to normal human volunteers in single doses of 200 mg to 800 mg. Results of these studies indicated that zileuton was well absorbed orally with an elimination half-life of approximately 2.5 hours. Leukotriene B4 production by ex vivo calcium ionophone stimulated whole blood was inhibited by up to 80% of baseline and correlated with plasma concentrations. Zileuton did not significantly inhibit cyclooxygenase as demonstrated by thromboxane B2 levels. There were no safety concerns that would preclude development.
authors.affiliation: Abbott Laboratories, Abbott Park, IL 60064-3500.
authors.forename: P
authors.initials: P
authors.lastname: Rubin
authors.forename: L
authors.initials: L
authors.lastname: Dubé
authors.forename: R
authors.initials: R
authors.lastname: Braeckman
authors.forename: L
authors.initials: L
authors.lastname: Swanson
authors.forename: R
authors.initials: R
authors.lastname: Hansen
authors.forename: D
authors.initials: D
authors.lastname: Albert
authors.forename: G
authors.initials: G
authors.lastname: Carter
mesh_terms: D000293:Adolescent; D000328:Adult; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D015289:Leukotrienes / Q000009:adverse effects / Q000096:biosynthesis* / Q000493:pharmacokinetics; D016859:Lipoxygenase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D008297:Male; D013931:Thromboxanes / Q000096:biosynthesis
chemical_list: D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D013931:Thromboxanes; C063449:zileuton; D006918:Hydroxyurea